Completed PHASE1 INTERVENTIONAL 1-arm NCT00575146

Ketogenic Diet for Recurrent Glioblastoma (ERGO)

Ketogenic Diet for Patients With Recurrent Glioblastoma

Sponsor: Evomed MedizinService GmbH

Interventions TAVARLIN

Updated 9 times since 2017 Last updated: Apr 16, 2014 Started: Dec 31, 2007 Primary completion: Feb 28, 2010 Completion: Feb 28, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Recurrent Glioblastoma, this trial is completed. The trial is conducted by Evomed MedizinService GmbH and has accumulated 9 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2023 — Jul 2024 [monthly]

Completed PHASE1
Dec 2022 — Jan 2023 [monthly]

Completed PHASE1

▶ Show 4 earlier versions

Dec 2021 — Dec 2022 [monthly]

Completed PHASE1
Jan 2021 — Dec 2021 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Dec 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Evomed MedizinService GmbH
University Hospital Tuebingen

Data source: University Hospital Tuebingen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Frankfurt, Germany
• Tübingen, Germany